We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Redhill Biopharma Ltd | NASDAQ:RDHL | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.0003 | 0.07% | 0.4333 | 0.42 | 0.4346 | 0.4378 | 0.4309 | 0.434 | 117,192 | 01:00:00 |
From May 2019 to May 2024
By Adria Calatayud
AstraZeneca PLC said Tuesday that it has agreed to sublicense global rights to its Movantik drug, a treatment for opioid-induced constipation, to RedHill Biopharma Ltd.
AstraZeneca said RedHill will make an upfront payment of $52.5 million on closing and a further noncontingent payment of $15 million in 2021. The deal excludes Europe, Canada and Israel, AstraZeneca said.
The FTSE 100-listed pharmaceutical company said Movantik generated sales of $96 million in the U.S. last year. AstraZeneca will continue to manufacture and supply Movantik to RedHill during a transition period, it said.
The divestment is expected to be completed in the first quarter of 2020, subject to closing conditions and regulatory clearances, AstraZeneca said. The agreement won't affect AstraZeneca's financial guidance for 2020, the company said.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
February 25, 2020 02:26 ET (07:26 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Redhill Biopharma Chart |
1 Month Redhill Biopharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
